Glycogen synthase kinase 3 (GSK3) is able to phosphorylate tau at many sites that are found to be phosphorylated in paired helical filaments in Alzheimer disease. Lithium chloride (LiCl) efficiently inhibits GSK3 and was recently reported to also decrease the production of amyloid- peptide (A) from its precursor, the amyloid precursor protein. Therefore, lithium has been proposed as a combined therapeutic agent, inhibiting both the hyperphosphorylation of tau and the production of A. Here, we demonstrate that the inhibition of GSK3 by LiCl induced the nuclear translocation of -catenin in Chinese hamster ovary cells and rat cultured neurons, in which a decrease in tau phosphorylation was observed. In both cellular models, a nontoxic concentration of LiCl increased the production of A by increasing the -cleavage of amyloid precursor protein, generating more substrate for an unmodified ␥-secretase activity. SB415286, another GSK3 inhibitor, induced the nuclear translocation of -catenin and slightly decreased A production. It is concluded that the LiCl-mediated increase in A production is not related to GSK3 inhibition.Alzheimer disease, the most frequent cause of dementia, is characterized by the presence of typical microscopic lesions in the brain of affected patients. The coexistence of intraneuronal neurofibrillary tangles and extracellular senile plaques allows confirmation of the clinical diagnosis of the disease (1).Neurofibrillary tangles are made of paired helical filaments (PHFs) 2 containing the microtubule-associated protein, tau (2-4). In Alzheimer disease, tau is hyperphosphorylated, and many serine and threonine residues (5, 6) that are found to be phosphorylated in PHF tau can be phosphorylated by GSK3 in both in vitro and transfected cells (7-9). Senile plaques contain an amyloid core that is mainly constituted of amyloid- peptide (A) (10), which is derived from the amyloid precursor protein (APP) (11,12). The APP gene encodes 10 different APP isoforms (13) with an amino acid content varying from 365 to 770 amino acids. The neuronal APP is a single pass type I transmembrane protein containing 695 amino acids (11) that is processed by amyloidogenic and nonamyloidogenic catabolic pathways. The -cleavage of APP, catalyzed by the well characterized aspartyl protease -site APP-cleaving enzyme 1 (BACE1) (14), produces a C-terminal fragment of APP (CTF), which is further cleaved by ␥-secretase to generate A. The ␥-secretase activity is found as a multiprotein complex containing at least four different proteins: Aph-1, nicastrin, presenilin, and Pen-2 (15, 16). APP can also be cleaved within the A sequence by an ␣-secretase. The ␣-cleavage of APP generates a soluble N-terminal fragment (s␣APP) and a 83-membrane-anchored C-terminal fragment (C83). Experimental evidence indicates that the ␣-cleavage of APP695 could be performed by members of the desintegrin and metalloprotease family, ADAM10 and ADAM17 (17). The short intracellular C-terminal domain of APP can be phosphorylated in vitro and in...